AbbVie forward PE ABBV

Share price divided by analysts' consensus earnings for the next twelve months, since 2012.

Today, Oct 23, 2026: 19.0×
10-year median: 12.2×
Against its 10-year history: 92nd; percentile: 0 is its lowest day, 100 its highest
10-year range: 6.8× to 22.3×
Peer median: 17.5×

AbbVie's forward PE is 19.0× as of Oct 23, 2026.

That is above its ten-year median of 12.2×, higher than on 92% of days in the last ten years.

Over that time it ranged from 6.8× in Mar 2020 to 22.3× in Nov 2024.

The median for 7 large drugmakers of a similar size is 17.5×.

Forward PE over time

median 12.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	19.0×	13.8×	19.0×
2025	18.3×	17.4×	22.1×
2024	19.5×	15.4×	22.3×
2023	14.7×	12.3×	14.8×
2022	13.7×	9.9×	13.9×
2021	10.2×	8.2×	10.2×
2020	9.0×	6.8×	9.8×
2019	9.5×	7.2×	10.5×
2018	10.7×	9.8×	17.7×
2017	13.9×	10.9×	15.0×
2016	12.1×	10.8×	13.9×
2015	13.0×	11.5×	18.0×
2014	18.3×	16.0×	19.8×
2013	18.6×	11.4×	18.6×
2012	11.6×	11.1×	11.9×

Against its peers

Companies in Drug Manufacturers - General nearest AbbVie's size, closest first, today.

Company	Forward PE
ABBVAbbVie	19.0×
JNJJohnson & Johnson	23.4×
MRKMerck	17.5×
AMGNAmgen	18.6×
LLYEli Lilly and	33.9×
GILDGilead Sciences	17.2×
PFEPfizer	10.9×
BMYBristol-Myers Squibb	10.4×
Peer median	17.5×

Where AbbVie ranks

#24of 51Healthcare stocks with the lowest forward PE

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on AbbVie

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.